Welcome Renal Team Members

You play a key position on the health team caring for your patients. Your role allows you to see that health care is not a one-size-fits-all approach. You also can see the importance of developing a customized treatment plan for each patient built around his or her strengths and weaknesses.

Helping You Make a Difference

The Online Resource to Help You Develop a Plan For Success With Your Patients

To help you respond to the needs of patients you encounter, we've developed this site and online materials specifically for you. Patients differ in what helps them gain a better understanding of their condition. Whether they require interactive online programs, downloadable brochures or educational games—online materials are available here to help.

These resources can save you time each day. So you can then concentrate more on being a better co-worker, educator, and advocate working to make a positive impact with your patients.

FOSRENOL^® First line. For reductions that last.*

Can help lower phosphorus levels within K/DOQI Guidelines within 2 weeks^1,2
An option that provides patients a similar long-term safety profile as the standard treatment³
A convenient calcium-free option for patients that can be taken with as little as 1 tablet per meal^†
A trusted choice that has been prescribed to more than 105,000 patients in the United States⁴

FOSRENOL^® is indicated to reduce serum phosphate in patients with end-stage renal disease.

* Maintenance of reduction was observed for up to 3 years in patients treated with FOSRENOL^®.

† Dosing based on three meals per day. Number of meals per day may vary. To achieve certain doses, additional tablets may be required.

Send to a Colleague

Important Safety Information

The most common adverse events were gastrointestinal, such as nausea and vomiting, and generally abated over time with continued dosing
The most common side effects leading to discontinuation in clinical trials were gastrointestinal events (nausea, vomiting, and diarrhea)
Other side effects reported in trials included dialysis graft complications, headache, abdominal pain, and hypotension
Although studies were not designed to detect differences in risk of fracture and mortality, there were no differences demonstrated in patients treated with FOSRENOL^® compared to alternative therapy for up to 3 years
The duration of treatment exposure and time of observation in the clinical program were too short to conclude that FOSRENOL^® does not affect the risk of fracture or mortality beyond 3 years
While lanthanum has been shown to accumulate in the GI tract, liver, and bone in animals, the clinical significance in humans is unknown
Patients with acute peptic ulcer, ulcerative colitis, Crohn's disease, or bowel obstruction were not included in FOSRENOL^® clinical studies. Caution should be used in patients with these conditions
FOSRENOL^® should not be taken by patients who are nursing or pregnant
FOSRENOL^® should not be taken by patients who are under 18 years of age

References

Data on file, Shire US Inc.
Eknoyan G, Levin A, Levin NW, for the National Kidney Foundation. Am J Kidney Dis. 2003;42(No. 4, suppl 3):S1-S201.
Finn WF, on behalf of the SPD405-307 Lanthanum Study Group. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol. 2006;65:191-202.
Verispan's Total Patient Tracker, December 2004—November 2007.

This site is strictly intended for US residents and is governed solely by US laws and governmental regulations. Please see our online privacy policy for more information.

While Shire US Inc. makes reasonable efforts to include accurate, up-to-date information on the site, Shire US Inc. makes no warranties or representations as to its accuracy. Shire US Inc. assumes no liability for any errors or omissions in the content of the site.

FOS1726 1/15/2008